002399.SZShenzhen Hepalink Pharmaceutical Group Co., Ltd.
82, and the US-China Tariff & API Source on 2027-02-10 is the next, with no anchor but a 50% bull probability. Both events are tied to the same underlying theme: the company’s ability to secure regulatory approval and maintain supply chain stability in a fragmented global market.
The schedule
- Wed25Nov
- Wed10Feb
Past
- Fri28Aug
Actual outcome: Bear · $9.48 at outcome
Shenzhen Hepalink reported EPS actual of 0.13, matching the estimate, but the stock fell 3.4% as price action indicated a bearish reaction. The lack of positive surprises in the CDMO segment recovery and heparin API pricing stability, combined with weak forward guidance, led to investor caution and a downward price movement.
Shenzhen Hepalink releases its H1 2026 interim financial results, closely watched for signs of CDMO segment recovery and heparin API pricing stability.
